A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...

Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate ...

Surgeon Gareth Honeybone wants wider access to zanidatamab to treat one of the deadliest cancers.

Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs. Now a team of researchers have discovered that this workhorse protein, called cereblon, in ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...